FIELD: medicine.
SUBSTANCE: invention refers to medicine and pharmaceutics, namely, to treating COVID-19 and its symptoms. Disclosed is use of 2-(imidazol-4-yl)-ethanamide of pentanedioic acid or a pharmaceutically acceptable salt thereof in the form of a solid dosage form for the treatment of COVID-19 and its symptoms, where dose of 2-(imidazol-4-yl)-ethanamide of pentanedioic acid or a pharmaceutically acceptable salt thereof ranges from 90 to 180 mg/day.
EFFECT: using the invention reduces the risk of post-covid symptoms and continuing symptomatic COVID-19, reduce the risk of developing the consequences of COVID-19 from the gastrointestinal tract, reduce the risk of developing respiratory consequences of COVID-19, accelerate the process of regeneration and recovery of pulmonary respiratory function in the process of treating COVID-19 and the post-covid period and expand the range of drugs for treating COVID-19 and its symptoms caused by various strains of the SARS-CoV-2 virus.
19 cl, 1 ex
